Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle glaucoma-a pilot study

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 5, 2010, Pages 497-501

  Yuan, Hongzhi ^a,b   Yu, Minbin ^a   Yang, Yangfan ^a   Wu, Kaili ^a   Lin, Xianchai ^a   Li, Jinrong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Taiping People's Hospital of Dongguan)   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TIMOLOL;

ADULT; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENOTYPE; HEART RATE; HUMAN; INTRAOCULAR PRESSURE; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; BRADYCARDIA; CYTOCHROME P-450 CYP2D6; FEMALE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; TIMOLOL;

EID: 77957935992     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0013     Document Type: Article

References (15)

1. Sit, A.J., and Liu, J.H. Pathophysiology of glaucoma and continuous measurements of intraocular pressure. Mol. Cell. Biomech. 6:57-69, 2009.
2. Lee, D.A., and Higginbotham, E.J. Glaucoma and its treatment: a review. Am. J. Health Syst. Pharm. 62:691-699, 2005.
3. Novack, G.D., O'Donnell, M.J., and Molloy, D.W. New glaucoma medications in the geriatric population: efficacy and safety. J. Am. Geriatr. Soc. 50:956-962, 2002.
4. Yang, Y., Wu, K., Yuan, H., and Yu, M. Cytochrome oxidase 2D6 gene polymorphsim in primary open-angle glaucoma with various effects to ophthalmic timolol. J. Ocul. Pharmacol. Ther. 25:163-171, 2009.
5. Volotinen, M. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab. Dispos. 35:1135-1141, 2007.
6. Leandro-Garciá, L.J., Leskelä , S., Montero-Conde, C., et al. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Anal. Biochem. 389:74-76, 2009.
7. Dorado, P., Cáceres, M., Pozo-Guisado, E., Wong, M.L., Licinio, J., and Llerena, A. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 39(10Suppl):S571-S754, 2005.
8. Sakuyama, K., Sasaki, T., Ujiie, S., Obata, K., Mizugaki, M., Ishikawa, M., and Hiratsuka, M. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos. 36:2460-2467, 2008.
9. Higgins, M.J., Rae, J.M., Flockhart, D.A., Hayes, D.F., and Stearns, V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J. Natl. Compr. Canc. Netw. 7:203-213, 2009.
10. Levo, A., Koski, A., Ojanperä , I., Vuori, E., and Sajantila, A. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic. Sci. Int. 135:9-15, 2003.
11. Shord, S.S., Cavallari, L.H., Gao, W., Jeong, H.Y., Deyo, K., Patel, S.R., Camp, J.R., Labott, S.M., and Molokie, R.E. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell Disease. Eur. J. Clin. Pharmacol. 65:651-658, 2009.
12. Monnin, J., Haffen, E., Sechter, D., and Vandel, P. Pharmacogenetics of depression in elderly patients. Psychol. Neuropsychiatr. Vieil. 7:43-55, 2009.
13. Dezentjé, V.O., Guchelaar, H.J., Nortier, J.W., van de Velde, C.J., and Gelderblom, H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin. Cancer Res. 15:15-21, 2009.
14. Nieminen, T., Uusitalo, H., Mäenpää , J., Turjanmaa, V., et al. Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. Eur. J. Clin. Pharmacol. 61:811-819, 2005.
15. Nieminen, T., Lehtimä ki, T., Mäenpää , J., Ropo, A., Uusitalo, H., and Kähönen, M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand. J. Clin. Lab. Invest. 67:237-245, 2007.